Hanmi Pharm Co Ltd (128940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩42.02 Billion ≈ $28.48 Million USD) by net assets (₩1.35 Trillion ≈ $911.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hanmi Pharm Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Hanmi Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 128940 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Hanmi Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanmi Pharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Union Semiconductor (Hefei) Co. Ltd. A
SHG:688403
|
N/A |
|
Koza Altin Isletmeleri AS
IS:KOZAL
|
0.128x |
|
SEB SA
PA:SK
|
0.141x |
|
GQG Partners Inc
AU:GQG
|
0.564x |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
-0.001x |
|
Tel Aviv Stock Exchange
TA:TASE
|
0.131x |
|
Turkiye Sise ve Cam Fabrikalari AS
IS:SISE
|
0.040x |
|
Guangzhou Haozhi Industrial Co Ltd
SHE:300503
|
0.011x |
Annual Cash Flow Conversion Efficiency for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hanmi Pharm Co Ltd from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Hanmi Pharm Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.24 Trillion ≈ $840.84 Million |
₩193.49 Billion ≈ $131.12 Million |
0.156x | -20.77% |
| 2023-12-31 | ₩1.10 Trillion ≈ $745.60 Million |
₩216.54 Billion ≈ $146.74 Million |
0.197x | +22.41% |
| 2022-12-31 | ₩1.01 Trillion ≈ $683.94 Million |
₩162.27 Billion ≈ $109.97 Million |
0.161x | -26.09% |
| 2021-12-31 | ₩928.26 Billion ≈ $629.07 Million |
₩201.92 Billion ≈ $136.84 Million |
0.218x | +19.42% |
| 2020-12-31 | ₩831.89 Billion ≈ $563.76 Million |
₩151.53 Billion ≈ $102.69 Million |
0.182x | +1103.39% |
| 2019-12-31 | ₩822.26 Billion ≈ $557.23 Million |
₩12.45 Billion ≈ $8.43 Million |
0.015x | -54.02% |
| 2018-12-31 | ₩789.26 Billion ≈ $534.87 Million |
₩25.98 Billion ≈ $17.61 Million |
0.033x | +141.47% |
| 2017-12-31 | ₩792.42 Billion ≈ $537.01 Million |
₩-62.91 Billion ≈ $-42.63 Million |
-0.079x | -114.12% |
| 2016-12-31 | ₩734.52 Billion ≈ $497.77 Million |
₩412.97 Billion ≈ $279.86 Million |
0.562x | +311.70% |
| 2015-12-31 | ₩744.81 Billion ≈ $504.75 Million |
₩101.71 Billion ≈ $68.93 Million |
0.137x | +345.18% |
| 2014-12-31 | ₩589.25 Billion ≈ $399.32 Million |
₩-32.82 Billion ≈ $-22.24 Million |
-0.056x | -129.98% |
| 2013-12-31 | ₩462.92 Billion ≈ $313.71 Million |
₩85.99 Billion ≈ $58.28 Million |
0.186x | +20.19% |
| 2012-12-31 | ₩409.34 Billion ≈ $277.41 Million |
₩63.27 Billion ≈ $42.88 Million |
0.155x | -4.64% |
| 2011-12-31 | ₩378.22 Billion ≈ $256.32 Million |
₩61.30 Billion ≈ $41.54 Million |
0.162x | +178.39% |
| 2010-12-31 | ₩325.38 Billion ≈ $220.50 Million |
₩18.94 Billion ≈ $12.84 Million |
0.058x | -- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more